Organogenesis Holdings Inc. (ORGO): Shareholders' Equity
$300.13M
As of 2025-12-31
$148.27M
As of 2026-06-30
+4.1%
3-year compound annual growth
+16.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $300.13M | +14.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $262.90M | -5.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $278.66M | +4.9% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $265.67M | n/a | 2025-02-27, Balance as of period end |
| 2022-03-31 | $241.53M | n/a | 2023-03-01, Balance as of period end |
| 2021-12-31 | $241.34M | +70.2% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $141.81M | +172.6% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $52.02M | n/c | 2022-03-01, Balance as of period end |
| 2018-12-31 | $47.04M | n/m | 2021-03-16, Balance as of period end |
| 2017-12-31 | -$15.32M | n/m | 2020-03-09, Balance as of period end |
| 2016-12-31 | -$15.98M | n/a | 2019-03-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Insmed Inc (INSM) | 2025-12-31 | $738.98M | +158.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $314.69M | +39.5% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $648.02M | +191.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$2.09B | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $114.83M | +94.4% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗